

18th Annual Conference of the British HIV Association (BHIVA)



Dr Cameron Holloway
University of Oxford

Comprehensive Cardiac Magnetic Resonance Reveals HIV is Associated with High Burden of Myocardial Disease

Cameron Holloway

University of Oxford

Centre for Clinical Magnetic Resonance Research

Disclosures: Nil



Background

- Higher incidence heart disease

- Untreated:

- Myocarditis
- Heart failure
- Pulmonary hypertension
- Pericardial effusion

- Why?

- Treated:


- Coronary disease
- Metabolic Complications
- ?Myocardial disease

- Management?

HIV -Cardiomyopathy







HIV -Cardiomyopathy





Function – 3D



Cardiac MR Imaging




Function

Fibrosis

T1 Mapping

Vascular
Distensibility



Hypotheses

- HIV related heart disease has multiple aetiologies which can be determined in a comprehensive study, including cardiac MR imaging and spectroscopy
- Metabolic derangements in chronic HIV infection lead to cardiac steatosis, energetic abnormalities and subsequent contractile dysfunction in patients with HIV
- cART
 - leads to cardiac lipodystrophy and mitochondrial abnormalities
 - alters central vascular function via modulation of circulating molecules associated with endothelial inflammation

Study Design


An observational study to
define the characteristics of
myocardial disease in patients
with HIV
&
Controls



Subjects with HIV
n = 104
ages >18 y.o.
range of disease duration &
severity

Controls
n = 39
Matched for age and co-morbidities

Recruitment in Outpatient clinics



Baseline Characteristics

	HIV	Control
Age (yrs)	44 ± 1	44 ± 1
Male (%)	77	67 *
MSM (%)	53	23 *
BMI (kg/m ²)	26 ± 1	25 ± 1
Heart rate (bpm)	64 ± 1	67 ± 2
Blood Pressure (mmHg)	131/78	133/79
Hypertension (%)	12 ± 3	8 ± 6
Smoking (%)	39	23 *
Hypercholesterolaemia (%)	13	15

• < 0.05 *

Plasma Metabolites

	HIV	Control
Cholesterol (mM)	4.5 ± 0.1	4.4 ± 0.2
HDL (mM)	1.1 ± 0.0	1.3 ± 0.1**
LDL (mM)	2.7 ± 0.1	2.7 ± 0.1
Chol/HDL	4.2 ± 0.1	3.6 ± 0.1 **
Triglyceride (mM)	1.6 ± 0.3	0.9 ± 0.2 **
Glucose (mM)	5.2 ± 0.1	4.9 ± 0.1*
Insulin (mU/l)	53 ± 3	46 ± 6
NEFAs (mM)	0.5 ± 0.1	0.5 ± 0.1


* < 0.05 ** < 0.01 *** < 0.001

Plasma Metabolites

	HIV	Control
Cholesterol (mM)	4.5 ± 0.1	4.4 ± 0.2
HDL (mM)	1.1 ± 0.0	$1.3 \pm 0.1^{**}$
LDL (mM)	2.7 ± 0.1	2.7 ± 0.1
Chol/HDL	4.2 ± 0.1	$3.6 \pm 0.1^{**}$
Triglyceride (mM)	1.6 ± 0.3	$0.9 \pm 0.2^{**}$
Glucose (mM)	5.2 ± 0.1	$4.9 \pm 0.1^*$
Insulin (mU/l)	53 ± 3	46 ± 6
NEFAs (mM)	0.5 ± 0.1	0.5 ± 0.1


* < 0.05 ** < 0.01 *** < 0.001

Cardiac Lipids



	HIV	Control
Cardiac fat (%)	0.59 ± 0.2	0.40 ± 0.2 **
Hepatic fat (%)	7.2 ± 3.4	2.1 ± 0.5 ***


* < 0.05 ** < 0.01 *** < 0.001



Cardiac Function

	HIV	Control
Ejection Fraction %	68 ± 1	71 ± 1 *
Peak Longitudinal Systolic strain rate	-12.4 ± 0.5	-14.2 ± 0.5 **
Peak Longitudinal Diastolic strain rate	36 ± 2	46 ± 6 ***
Peak Circumferential Systolic strain rate	-17.5 ± 0.2	-18.9 ± 0.5 **
Peak Circumferential Diastolic strain rate	71.5 ± 2	89.0 ± 6 ***
E/A	1.1 ± 0.0	1.3 ± 0.1 *


* < 0.05 ** < 0.01 *** < 0.001



Cardiac Function

	HIV	Control
Ejection Fraction %	68 ± 1	71 ± 1 *
Peak Longitudinal Systolic strain rate	-12.4 ± 0.5	-14.2 ± 0.5 **
Peak Longitudinal Diastolic strain rate	36 ± 2	46 ± 6 ***
Peak Circumferential Systolic strain rate	-17.5 ± 0.2	-18.9 ± 0.5 **
Peak Circumferential Diastolic strain rate	71.5 ± 2	89.0 ± 6 ***
E/A	1.1 ± 0.0	1.3 ± 0.1 *

* < 0.05 ** < 0.01 *** < 0.001





Cardiac Function

	cART	cART naïve
Ejection Fraction %	68 ± 1	64 ± 2 ***
Peak Longitudinal Systolic strain rate	-17.4 ± 0.5	-17.4 ± 0.5 *
Peak Longitudinal Diastolic strain rate	35 ± 2	41 ± 6
Peak Circumferential Systolic strain rate	-12.4 ± 0.2	-12.7 ± 0.5 *
Peak Circumferential Diastolic strain rate	71.5 ± 2	74.0 ± 6
E/A	1.2 ± 0.0	1.0 ± 0.1

* < 0.05 ** < 0.01 *** < 0.001

Cardiac MR findings



HIV

Control

Cardiac Fibrosis	88%	15% ***
------------------	-----	---------


*** <0.001

Conclusions

Asymptomatic patients with HIV:

- Metabolic abnormalities- lipids and glucose
- Increased cardiac lipids
- Alterations in cardiac function- cART naive
- Ongoing inflammation
- 88% have evidence of myocardial fibrosis
- Impaired vascular function (poster 113)

HIV -Cardiomyopathy



Conclusions

Asymptomatic patients with HIV:

- High burden of cardiac disease
- - Ongoing inflammation and metabolic risk
- cART – cardiometabolic abnormalities → LV dysfunction
- Implications for drug development and cART use

Cardiac abnormalities- HIV as a differential

Prospective drug studies are needed

The Research Team

HIV team:

Dr Lucy Dorrell
Dr Emma Wainwright
Dr Jackie Sherrard
Dr Brian Angus
Dr Chris Conlon
Dr Catherine Morgan
Gemma Hancock
Genevieve Clutton
Carol Cornish
Mags
Teresia
Dr Steve Dawson
Dr Jane Ashby



Cardiac MR team:

Dr Joseph Suttie
Dr Pete Cox
Dr Ntobeko Ntusi
Dr Masliza Mahmood
Professor Stefan Neubauer
Professor Kieran Clarke
Dr Theo Karamitsos
Philip Beak
Mina Asaad



External Collaborators

South Africa:
Dr Bongani Mayosi
Dr Richard Nethononda
Australia
Professor Kathy Samaras

